Supreme Court hears arguments in biosimilars "patent dance" case | PCMA President Merritt promotes PBMs on CNBC | Administration to continue funding cost-sharing subsidies
ADVERTISEMENT
April 27, 2017
FOLLOW PCMA ON TWITTER  Twitter
PCMA SmartBrief
News for the PBM Industry
SIGN UP ⋅   FORWARD ⋅   ARCHIVE
Featured Story
Supreme Court hears arguments in biosimilars "patent dance" case
The Supreme Court heard arguments in Novartis unit Sandoz' challenge to the requirement to notify the reference-product maker after FDA approval of a biosimilar and wait 180 days before marketing it.
Regulatory Focus (4/26) 
LinkedIn Twitter Facebook Google+ Email
PCMA President Merritt promotes PBMs on CNBC
Mark Merritt
LinkedIn Twitter Facebook Google+ Email
 
Legislative & Regulatory News
Administration to continue funding cost-sharing subsidies
Administration to continue funding cost-sharing subsidies
(Alex Wong/Getty Images)
The White House has told lawmakers it will continue funding cost-sharing reduction payments under the Affordable Care Act, withdrawing the threat that it might end the support from negotiations over government funding. However, the White House could still end the payments at any time, and AHIP spokeswoman Kristine Grow called for a congressional appropriation to give insurers the certainty they need.
Politico (4/26),  The Hill (4/26) 
LinkedIn Twitter Facebook Google+ Email
 
Health care vote possible this week if consensus is reached
Although House Speaker Paul Ryan, R-Wis., is focused this week on passing a funding bill to avert a government shutdown, a vote on revised health care legislation is still possible if it has enough support to pass, according to spokeswoman AshLee Strong. The House Freedom Caucus endorsed the bill, but moderate Republicans have not.
The Washington Post (tiered subscription model) (4/26),  CNN (4/26),  MSNBC (4/27) 
LinkedIn Twitter Facebook Google+ Email
CMS likely to miss deadline for IPAB report
The CMS chief actuary is expected to miss the Friday deadline for determining whether Medicare costs are rising fast enough to trigger the Independent Payment Advisory Board in 2018 as predicted last year by Medicare trustees.
InsideHealthPolicy.com (subscription required) (4/26) 
LinkedIn Twitter Facebook Google+ Email
Drug Industry Spotlight
Amgen's PCSK9 inhibitor misses sales mark
Sales of Amgen's new cholesterol drug Repatha, a PCSK9 inhibitor with a list price of $14,000 a year, were $49 million in the first quarter, compared with an average of $71.6 million expected by analysts.
Bloomberg (4/26) 
LinkedIn Twitter Facebook Google+ Email
$60B worth of pharma products to lose patents through 2020
Generic competition looms on about 40 brand-name drugs over the next three years, with combined revenue of about $60 billion, says Sanford Bernstein analyst Tim Anderson. Some of those drugs are biologics, Anderson notes.
STAT (tiered subscription model)/Pharmalot (4/26) 
LinkedIn Twitter Facebook Google+ Email
Cheap generic could prevent thousands of maternal deaths
Tranexamic acid can stop postpartum hemorrhage, which kills some 100,000 women every year and forces emergency hysterectomies in low- and middle-income countries, according to the results of a six-year study in The Lancet. The drug was invented in the 1950s, costs less than $2 per dose, does not need to be refrigerated and reduced the rate of maternal bleeding deaths by a third when given within three hours.
The New York Times (free-article access for SmartBrief readers) (4/26) 
LinkedIn Twitter Facebook Google+ Email
Other News
  
  
The empires of the future are the empires of the mind.
Winston Churchill,
statesman and prime minister
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about PCMA:
Upcoming PCMA Events | PCMA Newsroom
Become a PCMA Affiliate
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

Contact PCMA
Charles Cote
Vice President, Strategic Communications
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information